Molecular Therapy
Original Article

Caspase-8 Induces Lysosome-Associated Cell Death in Cancer Cells

Benfu Zhong,[1,2,4] Miao Liu,[1,3,4] Changsen Bai,[1] Yuxia Ruan,[1] Yuanyuan Wang,[1] Li Qiu,[1] Yang Hong,[1] Xin Wang,[1] Lifang Li,[1] and Binghui Li[1,2]

[1]Department of Cancer Cell Biology, Tianjin's Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China; [2]Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, P.R. China

Caspase-8, a well-characterized initiator of apoptosis, has also been found to play non-apoptotic roles in cells. In this study, we reveal that caspase-8 can induce cell death in a special way, which does not depend on activation of caspases and mitochondrial initiation. Instead, we prove that caspase-8 can cause lysosomal deacidification and thus lysosomal membrane permeabilization. V-ATPase is a multi-subunit proton pump that acidifies the lumen of lysosome. Our results demonstrate that caspase-8 can bind to the V_0 domain of lysosomal Vacuolar H^+-ATPase (V-ATPase), but not the V_1 domain, to block the assembly of functional V-ATPase and alkalinize lysosomes. We further demonstrate that the C-terminal of caspase-8 is mainly responsible for the interaction with V-ATPase and can suffice to inhibit survival of cancer cells. Interestingly, regardless of the protein level, it is the expression rate of caspase-8 that is the major cause of cell death. Taken together, we identify a previously unrevealed caspase-8-mediated cell death pathway different form typical apoptosis, which could render caspase-8 a particular physiological function and may be potentially applied in treatments for apoptosis-resistant cancers.

INTRODUCTION

The equilibrium between cell division and cell death is tightly controlled, and the useless or faulty elements can effectively be eliminated by regulated cell death.[1] There exist a number of patterns of cell death. Apoptosis, as the best known and characterized form of cell death, is characterized by morphologic changes such as cytoplasmic shrinkage, chromatin condensation, and DNA fragmentation, culminating with the formation of apoptotic bodies that can be removed by phagocytosis.[2] In contrast to apoptosis as an inherently controlled cellular death program, necrosis is a more troubled way of dying, and it is characterized by cellular swelling and plasma membrane rupture, leading to release of the cellular contents and inflammatory response and terminating with the disposal of cell corpses in the absence of chromatin condensation and lysosomal involvement. Lysosome-dependent cell death, as another type of cell death, is initiated by perturbations of intracellular homeostasis and demarcated by lysosomal membrane permeabilization (LMP).[2] It has recently become clear that there is crosstalk in the molecular mechanisms relevant to each form of cell death.

The initiation of apoptosis relies on the activation of a series of cysteine-dependent aspartyl-specific proteases known as caspases. There are two categories of apoptosis-associated caspases, the initiator caspases and the executioner caspases.[3] Caspase-8, as an apical caspase, is involved in the extrinsic pathway of apoptosis in answer to ligations of the death receptors. Ligand binding induces oligomerization of receptor and recruitment of the adaptor proteins (FADD),



Figure 1. Caspase-8 Initiates Cell Death in Cancer Cells

(A) Proliferation of HeLa and MCF-7 cells expressing vector or caspase-8 in 3 days. (B) Western blot analysis of classical apoptotic proteins (cleaved caspase-8, caspase-3/caspase-7, and PARP) in HeLa and MCF-7 cells after transfection with vector or caspase-8. (C) Cell death in MCF-7/VC3AI cells transfected with vector or caspase-8. Left panel, fluorescence images of MCF-7 cells expressing VC3AI, a caspase-3/caspase-7 activation indicator. Green fluorescence indicates apoptosis. Right panel, quantification of cell death of MCF-7/VC3AI cells based on the fluorescent cells. Scale bar, 100 μm. (D) Western blot analysis of cleavage of VC3AI in MCF-7/VC3AI cells after transfection with vector or caspase-8. (E) Caspase-8 overexpression induced apoptosis, as measured by annexin V/PI flow cytometric analyses. HeLa and MCF-7 cells were transfected with vector or caspase-8, and apoptotic cells (annexin V^+ PI^- and annexin V^+ PI^+) were detected by the binding of annexin V to externalized phosphatidylserine in conjunction with PI, which is a dye excluded from viable cells. Images of MCF-7 cells are shown in Figure S1A. Each bar represents the mean ± SD for triplicate experiments.

Lysosome is a membrane-bound organelle containing more than 50 soluble acid hydrolases, and its characteristic is the acidic lumen (pH 4.5–5.0), which is optimal for sets for hydrolase activity and conducive to macromolecule degradation.[9] Vacuolar H^+-ATPase (V-ATPase), a multi-component complex consisting of a membrane-immersed V_0 domain and cytosol-exposed V_1 domain, guarantees the acidic environment of lysosome and could utilize energy from ATP to transport protons from cytosol to the intralysosomal fraction against the electrochemical gradient. Therefore, V-ATPase plays a pivotal role in acidifying the lysosomes. Loss of function of V-ATPase, such as V_1 domain dissociation, can lead to lysosomal alkalinization, ending up with lysosomal dysfunction and/or LMP. LMP can then allow the leakage of intralysosomal contents to trigger cell death in a caspase-dependent or caspase-independent pathway.[10]

It has become clear that there is a tight connection between apoptosis and lysosome-dependent cell death. Lysosomal membrane rupture can provoke apoptosis, as cathepsins can catalyze the proteolytic activation or inactivation of several substrates, such as BID, BAX, anti-apoptotic Bcl-2 family proteins, and XIAP, which are involved in mitochondrial outer membrane permeabilization (MOMP).[11–13] In some circumstances, LMP appears to occur downstream of MOMP as a result of apoptotic signaling, forming an epiphenomenon of intrinsic apoptosis.[14] In our study, we report that caspase-8 can directly activate lysosome-associated cell death through inhibiting V-ATPase activity and initiating LMP but not depending on caspase activation and mitochondrial initiation. These findings expand our understanding of caspases and could be applied in treatments for apoptosis-resistant cancers.

RESULTS

Caspase-8 Overexpression Initiates Cell Death

Caspase-8, as an apical caspase, can initiate programmed cell death. In this study, we tested the effect of caspase-8 overexpression on HeLa and MCF-7 cells, two type II cell lines that relied on caspase-8-mediated cleavage and mitochondrial signal amplification.[15] Gain of function of caspase-8 was performed in HeLa and MCF-7 cells and the number of cells was examined. Our results showed that caspase-8 overexpression led to significantly decreased cell number in both cancer cells (Figure 1A). Additionally, the hallmarks of classical apoptotic proteins, including cleaved caspase-8, caspase-3, caspase-7, and the poly(ADP-ribose) polymerase (PARP), were induced by caspase-8 overexpression (Figure 1B). Furthermore, a biosensor, Venus-based caspase-3-like activity indicator (VC3AI), was utilized, and it is a cyclized dead fluorescence protein but can display green fluorescence upon cleavage by activated capsases.[16] As shown in Figure 1C, caspase-8 overexpression significantly activated VC3AI in MCF-7 cells based on green fluorescence, which was also confirmed by western blot analysis (Figure 1D). Annexin V/propidium iodide (PI) flow cytometric analyses also demonstrated that caspase-8 overexpression induced obvious apoptosis iV3(cells)-392MCF-7sedFigm04 1

B



overexpressing pro-caspase-8 in cells seems to initiate typical caspase-mediated cell death, consistent with previous reports that cell death is assumed to result from the auto-activation of exogenously expressing caspase-8.[17]

Caspase-8 Overexpression Induces Cell Death Independently of Its Catalytic Activity and Mitochondria

We speculated that the cancer cells overexpressing a mutated caspase-8 deprived of catalytic activity would not undergo significant cell death. Therefore, we constructed a catalytically inactive point mutant of caspase-8 (casp-8CI), C360S, that was proven to have no detectable apoptotic activity,[18] as well as an uncleavable double points mutant of caspase-8 (casp-8UC), D374A and D384A, that was not cleaved to form active dimers.[19] Surprisingly, we found that overexpression of both mutants in HeLa and MCF-7 cells still induced cell death at levels comparable to those that resulted from the wild-type caspase-8 (Figure 2A), but caspase-3 or caspase-7 was not cleaved by both mutants (Figure 2B). This result suggests that enzyme activity is not required for the cell death caused by overexpressing caspase-8.

Next, we tested whether the caspase-8-induced cell death was mediated through the mitochondrial pathway that was involved in the intrinsic





(Figure 3A), TNF-α-induced cell death was significantly reversed in HeLa cells (Figure 3B). However, cell death induced by caspase-8 overexpression was not rescued at all by BID knockdown (Figure 3C), suggesting that blocking the downstream pathway of caspase-8 in the apoptotic pathway has little effect on cell death induced by exogenously expressed caspase-8.

Next, we investigated whether the pro-apoptotic caspases were involved in cell death induced by caspase-8 overexpression. We first tested whether the activities of caspases were required for exogenous caspase-8-mediated cell death. A pan-caspase inhibitor, Z-VAD-FMK,[24] was used to treat HeLa cells, and we did not observed any protective effect against cell death by caspase-8 overexpression (Figure 3D). These results suggest that apoptotic caspases could not be involved in the cell death induced by exogenously expressed caspase-8.

To further exclude the involvement of caspases in exogenous caspase-8-triggerred cell death, we used the CRISPR/Cas9 system[25] to knock

Please cite this article in press as: Zhong et al., Caspase-8 Induces Lysosome-Associated Cell Death in Cancer Cells, Molecular Therapy (2020), https://doi.org/10.1016/j.ymthe.2020.01.022

apoptosis. Our results showed that the apoptotic proteins, including cleaved caspase-8 and caspase-3, were significantly induced in the wild-type and KO cells that re-expressed wild-type caspase-8, but not in the KO cells or those that re-expressed casp-8CI (Figure S4B) after TNF-α plus CHX treatment. We also observed significant dead cells (about 80%) in the wild-type and KO cells that re-expressed wild-type caspase-8, but not in casp-8-KO cells (Figure S4A). Interestingly, regardless of stimulation by TNF-α plus CHX, casp-8-KO cells re-expressing casp-8CI underwent cell death to a similar extent (Figure S4A). These results suggest that the enzymatic activity of caspase-8 is necessary for canonical extrinsic apoptosis but not for cell death revealed in our current study.

Although caspase-8 acted as the initiator of extrinsic apoptosis, it actually repressed MLKL-mediated necroptosis.[27] However, it was recently reported that the expression of enzymatically inactive capase-8 could cause embryonic lethality in mice by inducing necroptosis and pyroptosis in some specific tissues.[28,29] Therefore, we next investigated whether necroptosis and pyroptosis were involved in casp-8CI-induced cell death. We treated the wild-type or 4KO HeLa cells with the RIPK1 inhibitor necrostatin-1 (Nec-1) or the MLKL inhibitor necrosulfonamide (NSA) and found that cell death in both wild-type and 4KO HeLa cells induced by casp-8CI expression was not inhibited at all by Nec-1 or NSA (Figure S5), suggesting that the cell death induced by exogenous casp-8CI is not necroptosis. In fact, the pan-caspases inhibitor Z-VAD-FMK and NSA also blocked pyroptotic death by suppressing the cleavage of gasdermin D (GSDMD), the pore-forming effector protein of pyroptosis.[30,31] Taken together, these results actually exclude the involvement of pyroptosis and necroptosis.

Caspase-8 Is Functionally Linked to the Stability of Lysosomes in Cancer Cells

Interestingly, exogenous caspase-8 expression substantially triggered typical apoptotic events (Figure 1), although it elicited cell death completely independent of these pathways (Figures 2 and 3). Among cell death types reported up to date, damaged lysosomes can release hydrolases to elicit cell death and meanwhile they often activate the typical apoptotic pathways (Figure S6A).[9,10,13,32]. In this study, we used chloroquine (CQ), a lysosomotropic agent that diffuses through membranes to accumulate and quench the acidic pH in lysosomes and thus leads to lysosome rupture,[33] to confirm that lysosomal damage indeed induced apoptotic events, including caspase activation and PARP cleavage in MCF-7 and HeLa cells (Figures S6B and S6C), precisely as for caspase-8 overexpression. Therefore, we next investigated whether lysosomes were involved in caspase-8-induced cell death. We first examined the subcellular localization of endogenous caspase-8 in HeLa cells. The immunofluorescence imaging showed that caspase-8 was partially co-localized with lysosome-associated membrane protein 1 (LAMP1), routinely a lysosome marker,[34] suggesting that caspase-8 may interact with lysosomes (Figure 4A). We then tried to determine the effect of exogenously expressed caspase-8 on lysosomes. Caspase-8-GFP was transiently transfected into 4KO HeLa cells, and at 48 h post-transfection cells were stained with LysoTracker red, a red fluorescent dye that stains acidic organelles.[35] We found that cells with caspase-8-GFP showed significantly decreased intensity of LysoTracker red fluorescence compared to the adjacent cells without caspase-8-GFP (Figures 4B and 4C). These results suggest that exogenously expressed caspase-8 could cause the dysfunction in lysosomes via dysregulating the acidic lumens.

Furthermore, 4KO cells were transfected with caspase-8 or treated with bafilomycin A1, a V-ATPase inhibitor,[36] and then stained with a LysoSensor green dye that becomes more fluorescent in an acidic environment and shows reduced fluorescence upon lysosomal alkalinization.[37] Flow cytometric analyses showed that caspase-8 overexpression decreased the LysoSensor green fluorescence intensity in 4KO HeLa cells, similar to bafilomycin A1, a positive control for lysosomal alkalinization[36] (Figures 4D and 4E; Figure S7A), suggesting the occurrence of lysosomal alkalinization. This speculation was further confirmed by the results with a sensitive cytochemical technique that permits visualization of the stability of lysosomes in living cells using acridine orange (AO) relocation and uptake methods. AO is a lysosomotropic base that accumulates in normal lysosomes, emitting bright red fluorescence under blue or green excitation light. When AO-loaded lysosomes are damaged, AO is released to the cytosol without fluorescence, and thus the intensity of red fluorescence in AO-exposed cells reflects the number of intact lysosomes.[9] We found that caspase-8 expression, as well as bafilomycin A1, induced subdued and dispersed red fluorescence in 4KO HeLa cells (Figures 4F and 4G; Figure S7B), indicating the lysosomal damage.

As LMP resulting from lysosomal damage is a critical factor for cell death induction, we next determined the effect of exogenously expressed caspase-8 on LMP in 4KO HeLa cells using the tool of GFP-LGALS3. LGALS3/galectin-3, as a sugar-binding protein, was reported as being best suitable for LMP detection due to its widespread expression and rapid translocation to leaky lysosomes to bind lysosomal membrane sugar proteins.[38] Therefore, the detection of GFP-LGALS3 puncta can indicate LMP. Our results showed that after treatment with L-leucyl-L-leucine methyl ester (LLOMe), a known LMP inducer,[39] GFP-LGALS3 in 4KO HeLa cells formed puncta that were exclusively stained with LysoTracker red (Figure 4H). Importantly, caspase-8 expression induced the exactly similar GFP-LGALS3 puncta in 4KO HeLa cells (Figure 4H), strongly demonstrating the presence of lysosomal rupture. In addition, cathepsin L, the lysosomal cysteine protease, was examined by an immunofluorescence assay to determine whether the contents of lysosomes were permeated into cytoplasm. Our results showed that the granular distribution of cathepsin L was shifted into dispersion by caspase-8 expression in 4KO HeLa cells (Figure 4I). The maturation of cathepsin L was also enhanced by caspase-8 expression in 4KO HeLa cells (Figure 4I). Taken together, our results demonstrate that caspase-8 induces lysosome-associated cell death.

Caspase-8 Is Associated with the V_0 Domain of V-ATPase *In Vivo*

V-ATPases are the ATP-dependent proton pumps that transport protons from the cytoplasm into the lumen of lysosome to maintain the



A
B
D
LAMP1
Casp-8
DAPI
Merge
LysoTracker
Casp-8-GFP
Hoechst
Merge
Vector
Casp-8
ATPase inhibitor
Count
FITC-A
PE-Cy5-A
7.34
54.3
25.2
0.48
31.3
84.3
F
G
H
GFP-LGALS3
LysoTracker
LLOME
C
Casp8-GFP
GFP
GAPDH
E
I
Numbers of GFP puncta/cell



acidic environment in lysosome.[40] Nonfunctional V-ATPases are reported to be associated with cell death.[40]

To gain a mechanistic insight into the caspase-8-mediated rupture of lysosomes, total proteins from HeLa cells were extracted and co-immunoprecipitation (coIP) experiments were performed with antibodies detecting the endogenous proteins. coIP with antibodies against caspase-8 followed by immunoblotting (IB) with antibodies against subunit a or d in the V_0 domain (subunit V_0a or V_0d), or against subunit A or C in the V_1 domain (subunit V_1A or V_1C) of V-ATPase, revealed that caspase-8 interacts with the components of the V_0 domain, but not the members in the V_1 domain (Figure 5A). Reciprocally, coIP with antibodies against subunit V_0a of V-ATPase followed by IB with antibodies against caspase-8 also demonstrated that caspase-8 was efficiently co-immunoprecipitated by subunit V_0a of V-ATPase (Figure 5B). The interaction between caspase-8 and subunit V_0a was also confirmed by coIP experiments in HeLa cells with caspase-8-GFP or FLAG-V_0a expression (Figure S8). In contrast, caspase-3, caspase-7, and caspase-9 were not co-immuno-



activity.[41] In order to determine whether caspase-8 could block the assembly of V-ATPase by associating with the V_0 domain of V-ATPase, we performed coIP experiments on the overexpression of caspase-8. The results show that the association of V_0 subunits with V_1 subunits was reduced by caspase-8 expression (Figure 5F), indicating that overexpression of caspase-8 inhibits the structural integrity of V-ATPase in cancer cells.

P10 Domain of Caspase-8 Is Involved in Lysosome-Associated Cell Death

As the P10 region of caspase-8 was required for the interaction of caspase-8 with the V_0 domain of ATPase, and to understand the biological significance of P10, we next investigated the effect of P10 on cell survival. To this end, 4KO HeLa cells were transfected with the GFP-fused deletion mutants of caspase-8 (Figure 5D). At 48 h after transfection, cell death was examined. Notably, overexpression of GFP-P10 of caspase-8 exerted more significant positive effects on cell death than did other deletion mutants (Figures 6A and 6B).

To consolidate the involvement of P10 in inhibiting the V-ATPase-mediated maintenance of lysosomal homeostasis, CQ was utilized



activated by steroid ligands, such as estradiol (E2), and expressed in ER$^+$ breast cancer cells, including MCF-7. Therefore, we delivered this system to MCF-7 cells by lentivirus, and it was supposed that E2 would activate ER to promote rtTA expression, and may further induce caspase-8-mediated cell death in the presence of DOX (Figure 7B). Our results indeed showed that DOX significantly led to cell death in MCF-7 cells depending on E2, compared to the individual treatments (Figure 7C). Similarly, we could generate tumor-specific enhancer- or promoter-controlled Tet-On caspase-8 and deliver them *in vivo* by adeno-associated virus (AAV) or other feasible vehicles. In this way, we can convert tumor-specific enhancers or promoters to the targets of cancers by DOX.

Intriguingly, the expression of caspase-8 on E2 and/or DOX was not correlative with cell death (Figure 7C). Although E2 or DOX alone did not significantly trigger cell death, they also obviously gave rise to

caspase-8 expression, which most likely resulted from the leaking expression. As such, exogenous caspase-8-induced cell death could be mediated by the expression rate but not the protein level. In order to test this speculation, we induced caspase-8 expression with different concentrations of DOX (1 nM to 50 nM) in the Tet-On caspase-8 HeLa cells. We noticed that although the expressions of caspase-8 were nearly increased to the same level after 48 h of DOX induction at all of the concentrations, 1 nM DOX induced far fewer dead cells than did others (Figure 7D). We then measured caspase-8 expression of Tet-On HeLa cells treated with 1 and 10 nM DOX at the different times and observed that 1 nM DOX-induced caspase-8 expression was indeed slower when compared to that by 10 nM DOX, although their protein levels almost reached to the flat even upon 12-h DOX induction (Figure 7E). To exclude the possibility that 1 nM DOX could take a long time to kill cells, we extended DOX treatments for days and found that cells upon induction with 10 nM DOX completely died, but those treated with 1 nM DOX survived and grew well. We then kept on culturing these cells with 1 nM DOX in the culture medium, and no significant cell death was observed. In fact, these cells proliferated normally despite that caspase-8 expression was sustained at a high level (Figure 7F). These results suggest that the fast expression rate of caspase-8 could be the main cause of induced cell death. Upon fast expression, caspase-8 could not be fully folded or partnered in time by its chaperonins, and then the immature capsase-8 probably elicits cell death.

DISCUSSION

In this study, we reveal that caspase-8 can potentially induce cell death via interacting with the V_0 domain of lysosomal V-ATPase to damage lysosomes, regardless of caspase activation and mitochondrial initiation (Figure 6E).

There was evidence that lysosomal V-ATPase activity can be controlled by different mechanisms, including regulating the assembly of V-ATPase, modulation of V-ATPase trafficking, and regulating the expression of V-ATPase subunits.[41] Especially, V-ATPase activity *in vivo* is regulated via the unique mechanism referred to as "reversible dissociation," a process that results in a transient pool of free cytosolic V_1 and membrane integral V_0 sectors that are functionally silenced.[41]

Therefore, it is possible that if some stimuli can promote endogenous caspase-8 expression, they should also give rise to cell death, complementary to other types of cell death, and may exert physiological or pathological roles.

Our results show that caspase-8 can directly induce LMP in an apoptosis-resistant cell model (Figure 4). Since LMP can trigger apoptosis by attacking mitochondria,[10] lysosome-associated cell death is most often covered by apoptosis, as indicated in Figure 1. In fact, apoptotic stimuli can liberate caspase-8 in an active form, and thus during apoptosis the activated capsase-8 could also elicit lysosome-dependent cell death at the same time. For instance, in the late stage of apoptosis, apoptotic cells are often accompanied with the plasma membrane rupture,[48] which could result from caspase-8-associated lysosome-mediated necrosis.

In caspase-related apoptosis, the anti-apoptotic Bcl-2 family proteins promote cancer cell survival by sequestering the pro-apoptotic proteins such as BID and BAX that act on the mitochondrial outer membrane to release cytochrome *c* and subsequently to activate the intrinsic apoptosis pathway through a caspase cleavage cascade.[4] Indeed, several Bcl-2 antagonists are in clinical trials for cancer treatment. Nevertheless, these therapeutic agents are limited by the high expression of Mcl-1 and other molecular mechanisms that confer drug resistance.[20] We report in the current study that the Bcl-2-blocked caspase pathway can be potentially circumvented by caspase-8 that interacts with V-ATPase to directly target lysosomes. Therefore, our results suggest a biologic significance that to promote caspase-8 expression is a potential therapeutic strategy for cancers with high expression of anti-apoptotic Bcl-2 family proteins, or for cancers resistant to the small-molecule inhibitors of Bcl-2. In addition, it was recently reported that mitochondria density in cells is a source of cell-to-cell variability, and cancer cells with high mitochondria density tend to resist TRAIL-induced cell death.[49] Accelerating the expression of caspase-8 or its functional part could also be a plausible means to kill such subsets of cancers with high mitochondria density. We prove that the P10 fragment of caspase-8 can efficiently associate with the V_0 domain of V-ATPase, induce cell death, and also sensitize cells to lysosomotropic agents. Furthermore,TRA

red (L7528) and LysoSensor green (L7535) were obtained from Invitrogen. Z-VAD-FMK and ABT-737 were provided by BioVision Technologies. An annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (556547) was purchased from BD Biosciences. Protein A/G PLUS-agarose (sc-2003) was purchased from Santa Cruz. LLOME (sc-285992) was from Santa Cruz. Puromycin and blasticidin were purchased from Invitrogen, and G418 was from Gibco. Antibodies used were as follows: anti-caspase-8 (Cell Signaling Technology, #4790, Cell Signaling Technology, #9746, Proteintech, 13423-1-AP, 1:150 for immunofluorescence [IF] and 1:1,000 for western blot); anti-caspase-3 (Cell Signaling Technology, #9662, 1:1,000 for western blot); anti-cleaved caspase-3 (Wanleit, WL01857, 1:500 for western blot); anti-caspase-7 (Cell Signaling Technology, #9494, 1:1,000 for western blot); anti-caspase-9 (Proteintech, 66169-1-Ig, 10380-1-AP, 1:1,000 for western blot); anti-V_0d (Proteintech, 18274-1-AP, 1:1,000 for western blot); anti-V_1C (Proteintech, 16054-1-AP, 1:1,000 for western blot); anti-V_1A (Proteintech, 17115-1-AP, 1:1,000 for western blot); anti-V_0a (Santa Cruz, sc-374475, 1:100 for IF and 1:600 for western blot); anti-GFP (Proteintech, 50430-2-AP, 66002-1-Ig, 1:6,000 for western blot); anti-GAPDH (Proteintech, 60004-1-Ig, 10494-1-AP, 1:8,000 for western blot); anti-β-actin (Sigma, A5316, 1:5,000 for western blot); anti-PARP (Cell Signaling Technology, 9542, 1:1,000 for western blot); anti-Bcl-2 (Abcam, #ab692, 1:1,000 for western blot); anti-Bcl-x_L (Abcam, #ab77571, 1:500 for western blot); anti-LAMP1 (Abcam, #ab24170, 1:100 for IF); anti-cathepsin L (Abcam, #ab133641, 1:150 for IF); anti-mature cathepsin L (BioVision Technologies, 3741, 1:1,000 for western blot); and anti-FLAG (Proteintech, 66008-2-lg, 1:5,000 for western blot).

CoIP and Western Blot

Cellular lysates were prepared by incubating the cells in lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.3% Nonidet P-40, 2 mM EDTA) containing protease inhibitor cocktail (Roche) for 40 min at 4°C, followed by centrifugation at 12,000 × *g* for 15 min at 4°C. The protein concentration of the lysates was determined by a bicinchoninic acid (BCA) protein assay kit (Pierce) according to the manufacturer's protocol. For immunoprecipitation, 500 μg of protein was incubated with 2 μg of specific antibodies for 12 h at 4°C with constant rotation; 50 μL of 50% protein A or G agarose beads was added and incubated for an additional 3 h at 4°C. Beads were then washed five times using the lysis buffer. Between washes, the beads were collected by centrifugation at 1,000 × *g* for 3 min at 4°C. The precipitated proteins were eluted from the beads by resuspending the beads in 2× SDS-PAGE loading buffer and boiling for 10 min. The resultant materials from immunoprecipitation or cell lysates were resolved using SDS-PAGE gels and transferred onto nitrocellulose membranes. For routine western blot, cells were washed twice with cold PBS, then lysed in buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium vanadate, 1 mg/mL leupeptin, 1 mM phenylmethanesulfonylfluoride). Equal amounts of protein were loaded onto SDS-PAGE and transferred onto polyvinylidene fluoride (PVDF) blotting membranes. Membranes were incubated with appropriate antibodies for 1 h at room temperature or overnight at 4°C followed by incubation with a secondary antibody. Immunoreactive bands were detected by a LI-COR Biosciences Odyssey image reader (LI-COR Biosciences, USA), or they were visualized using western blotting luminol reagent (Santa Cruz) according to the manufacturer's recommendations.

Wound-Healing Assay and Cell Invasion Assay

For the wound-healing assay, 1×10^6 cells were seeded into each well of a six-well plate and the next day the cellular monolayer was wounded by scratching with a 20-μL pipette tip. The cells were washed three times with PBS and added to serum-free medium. The distances of cell migration were calculated by subtracting the distance between the wound edges at 0, 12, 24, 36, and 48 h from the distances measured at 0 h. The transwell invasion assay was performed with transwell chambers (BD Biosciences). Cells were washed three times in PBS and resuspended in serum-free culture medium. Afterward, 8×10^4 cells in 200 μL of serum-free medium were plated onto the upper chamber of the transwell, and 500 μL of DMEM supplemented with 10% FBS was add to the lower chambers. After incubating for 15 h, cells may actively migrate from the upper to the lower side of the filter due to FBS as an attractant. Cells on the upper side were removed using cotton swabs, and the invasive cells on the lower side were stained with a three-step stain set (Thermo Fisher Scientific) and counted using a light microscope.

Colony Formation Assay

1×10^3 cells were maintained in culture media in six-well plates for 14 days, fixed with 4% paraformaldehyde, stained with 0.1% crystal violet for colony observation, and counted using a light microscope. Each experiment was performed in triplicate and repeated at last three times.

Proliferation Assay

Cells were plated in triplicate in 12-well plates at 1×10^5 cells per well in 1.5 mL of medium. After days, as indicated in experiments, wells were washed twice with PBS to remove dead cells, and then the entire contents of the well were trypsinized. Cell number was determined using a hemocytometer. For each well, the fold change in cell number relative to day 0 was presented directly or in a $\log_2$ scale.

Cell Death Assay

Dead cells were negatively corresponding to the ATP level. Therefore, the level of ATP was examined through the CellTiter-Glo luminescent cell viability assay kit (Promega, #7570), and the percentage of dead cells was calculated by subtracting the percentage of living cells from 100%. 1.5×10^5 cells per well were seeded in 12-well plates. After the desired treatment, 200 μL of CellTiter-Glo reagent was added to each well after the medium was removed. Subsequently, plates were placed on a shaker for 10 min and were then incubated at room temperature for an additional 10 min. Luminescence reading was carried out with a SpectraMax M2 reader (Molecular Devices).

Annexin V/PI Flow Cytometric Analysis

Cells were seeded in six-well plates at 1.5×10^5 cells per well. After transfection for 24 h, the suspended and scraped cells were pooled, pelleted by centrifugation, washed with ice-cold PBS, and resuspended in 200 μL of 1× binding buffer (annexin V-FITC/PI apoptosis detection kit, BD, USA). Next, the cell suspension was transferred to a 5-mL tube and incubated with 5 μL of annexin V-FITC for 15 min at 25°C followed by 5 μL of PI for 5 min at 25°C in the dark. Finally, samples were analyzed by flow cytometry within 1 h on a FACScan flow cytometer (BD Biosciences). The results are presented as the percentage of cells that were apoptotic (annexin V^+ PI^- or annexin V^+ PI^+).

Lysosomal Acidification Assessment

1.5×10^5 cells per well were grown in six-well plates, and after the desired treatment, cells were stained with AO (1.5 μg/mL) dissolved in complete growth medium for 15 min at 37°C, and then washed twice with warm PBS. The cells were rapidly imaged with a microscope (Operetta CLS, PerkinElmer). For flow cytometry analysis, a cell suspension containing 300 μL of PBS was prepared in a fluorescence-activated cell sorting (FACS) tube. Red fluorescence intensity of cells was measured by flow cytometry (FACSCanto II, BD Biosciences) in the far-red channel (phycoerythrin [PE]-Cy5). For LysoSensor green, cells were stained with 1 μM LysoSensor green for 15 min at 37°C and measured by a flow cytometer in the FITC channel. To evaluate lysosomal integrity, cells were incubated with 0.5 μM LysoTracker red at 37°C for 5 min. Hoechst was included in the final washing to stain nuclei. Images were visualized with an Olympus inverted microscope equipped with a charge-coupled camera.

Immunofluorescence

MCF-7 or HeLa cells were grown on 12-well chamber slides. After the desired treatment, cells were washed with PBS, fixed in 4% (w/v) paraformaldehyde for 20 min, permeabilized with 0.1% (v/v) Triton X-100 in PBS for 10 min, blocked with 3% BSA, and incubated with appropriate primary antibodies followed by staining with matching Alexa Fluor (AF) 488- or AF594-coupled secondary antibodies (Life Technologies, A-11008, A-11001, A-11005, A-11012, 1:150). The cells were washed four times, and a final concentration of 0.1 μg/mL DAPI (Sigma) was included in the final washing to stain nuclei. Images were visualized with a fluorescence microscope (Zeiss Imager Z2).

LMP Assay

Cells stably expressing GFP-LGALS3 were grown on 12-well plates. After the desired treatment, the cells were stained with LysoTracker red to label lysosomes. Images of LGALS3 distribution were visualized with an Olympus inverted microscope equipped with a charge-coupled camera. The filter sets for imaging were as follows: GFP, excitation (Ex) 480/30 nm, DM505, BA535/40; red fluorescent protein (RFP), Ex535/50 nm, DM575, BA590.

Statistical Analysis

Data are given as mean ± SD for triplicate experiments unless specified otherwise.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.ymthe.2020.01.022.

AUTHOR CONTRIBUTIONS

B.Z., M.L., and L.L. performed experiments and analyzed data. C.B., Y.R., Y.W., Y.H., and L.Q. provided technical assistance. X.W. provided funding support and some ideas. M.L., L.L., and B.L. designed the study and wrote the manuscript.

CONFLICTS OF INTEREST

The authors declare no competing interests.

ACKNOWLEDGMENTS

This work was supported by Grants 81672762, 81472472, and 81902811 from the National Natural Science Foundation of China.

REFERENCES

1. Bröker, L.E., Kruyt, F.A., and Giaccone, G. (2005). Cell death independent of caspases: a review. Clin. Cancer Res. *11*, 3155–3162.
2. Galluzzi, L., Vitale, I., Aaronson, S.A., Abrams, J.M., Adam, D., Agostinis, P., Alnemri, E.S., Altucci, L., Amelio, I., Andrews, D.W., et al. (2018). Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. *25*, 486–541.
3. Pellegrini, M., Bath, S., Marsden, V.S., Huang, D.C., Metcalf, D., Harris, A.W., and Strasser, A. (2005). FADD and caspase-8 are required for cytokine-induced proliferation of hemopoietic progenitor cells. Blood *106*, 1581–1589.
4. Estaquier, J., Vallette, F., Vayssiere, J.L., and Mignotte, B. (2012). The mitochondrial pathways of apoptosis. Adv. Exp. Med. Biol. *942*, 157–183.
5. Rosenberg, S., Zhang, H., and Zhang, J. (2011). FADD deficiency impairs early hematopoiesis in the bone marrow. J. Immunol. *186*, 203–213.
6. Gringhuis, S.I., Kaptein, T.M., Wevers, B.A., Theelen, B., van der Vlist, M., Boekhout, T., and Geijtenbeek, T.B. (2012). Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1β via a noncanonical caspase-8 inflammasome. Nat. Immunol. *13*, 246–254.
7. Boege, Y., Malehmir, M., Healy, M.E., Bettermann, K., Lorentzen, A., Vucur, M., Ahuja, A.K., Böhm, F., Mertens, J.C., Shimizu, Y., et al. (2017). A dual role of caspase-8 in triggering and sensing proliferation-associated DNA damage, a key determinant of liver cancer development. Cancer Cell *32*, 342–359.e10.
8. Keller, N., Ozmadenci, D., Ichim, G., and Stupack, D. (2018). Caspase-8 function, and phosphorylation, in cell migration. Semin. Cell Dev. Biol. *82*, 105–117.
9. Brunk, U.T., Neuzil, J., and Eaton, J.W. (2001). Lysosomal involvement in apoptosis. Redox Rep. *6*, 91–97.
10. Wang, F., Gómez-Sintes, R., and Boya, P. (2018). Lysosomal membrane permeabilization and cell death. Traffic *19*, 918–931.
11. Taniguchi, M., Ogiso, H., Takeuchi, T., Kitatani, K., Umehara, H., and Okazaki, T. (2015). Lysosomal ceramide generated by acid sphingomyelinase triggers cytosolic cathepsin B-mediated degradation of X-linked inhibitor of apoptosis protein in natural killer/T lymphoma cell apoptosis. Cell Death Dis. *6*, e1717.
12. Bidère, N., Lorenzo, H.K., Carmona, S., Laforge, M., Harper, F., Dumont, C., and Senik, A. (2003). Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. J. Biol. Chem. *278*, 31401–31411.
13. Droga-Mazovec, G., Bojic, L., Petelin, A., Ivanova, S., Romih, R., Repnik, U., Salvesen, G.S., Stoka, V., Turk, V., and Turk, B. (2008). Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. J. Biol. Chem. *283*, 19140–19150.
14. Plotegher, N., and Duchen, M.R. (2017). Mitochondrial dysfunction and neurodegeneration in lysosomal storage disorders. Trends Mol. Med. *23*, 116–134.

Please cite this article in press as: Zhong et al., Caspase-8 Induces Lysosome-Associated Cell Death in Cancer Cells, Molecular Therapy (2020), https://doi.org/10.1016/j.ymthe.2020.01.022

15. Uthaisang-Tanechpongtamb, W., Sriyabhaya, P., and Wilairat, P. (2013). Role of altholactone in inducing type II apoptosis signalling pathway and expression of cancer-related genes in cervical carcinoma HeLa cell line. Cell Biol. Int. *37*, 471–477.

16. Zhang, J., Wang, X., Cui, W., Wang, W., Zhang, H., Liu, L., Zhang, Z., Li, Z., Ying, G., Zhang, N., and Li, B. (2013). Visualization of caspase-3-like activity in cells using a genetically encoded fluorescent biosensor activated by protein cleavage. Nat. Commun. *4*, 2157.

17. Li, M., Wu, X.M., Gao, J., Yang, F., Zhang, C.L., Ke, K., Wang, Y.C., Zheng, Y.S., Yao, J.F., Guan, Y.Y., et al. (2018). Mutations in the P10 region of procaspase-8 lead to chemotherapy resistance in acute myeloid leukemia by impairing procaspase-8 dimerization. Cell Death Dis. *9*, 516.

18. Hu, W.H., Johnson, H., and Shu, H.B. (2000). Activation of NF-κB by FADD, Casper, and caspase-8. J. Biol. Chem. *275*, 10838–10844.

19. Keller, N., Mares, J., Zerbe, O., and Grütter, M.G. (2009). Structural and biochemical studies on procaspase-8: new insights on initiator caspase activation. Structure *17*, 438–448.

20. Lam, L.T., Zhang, H., and Chyla, B. (2012). Biomarkers of therapeutic response to BCL2 antagonists in cancer. Mol. Diagn. Ther. *16*, 347–356.

21. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K.J., Debatin, K.M., Krammer, P.H., and Peter, M.E. (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J. *17*, 1675–1687.

22. Hellwig, C.T., Kohler, B.F., Lehtivarjo, A.K., Dussmann, H., Courtney, M.J., Prehn, J.H., and Rehm, M. (2008). Real time analysis of tumor necrosis factor-related apoptosis-inducing ligand/cycloheximide-induced caspase activities during apoptosis initiation. J. Biol. Chem. *283*, 21676–21685.

23. Li, H., Zhu, H., Xu, C.J., and Yuan, J. (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell *94*, 491–501.

24. Garcia-Calvo, M., Peterson, E.P., Leiting, B., Ruel, R., Nicholson, D.W., and Thornberry, N.A. (1998). Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol. Chem. *273*, 32608–32613.

25. Sanjana, N.E., Shalem, O., and Zhang, F. (2014). Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods *11*, 783–784.

26. Kline, M.P., Rajkumar, S.V., Timm, M.M., Kimlinger, T.K., Haug, J.L., Lust, J.A., Greipp, P.R., and Kumar, S. (2007). ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia *21*, 1549–1560.

27. Oberst, A., Dillon, C.P., Weinlich, R., McCormick, L.L., Fitzgerald, P., Pop, C., Hakem, R., Salvesen, G.S., and Green, D.R. (2011). Catalytic activity of the caspase-8-FLIP$_L$ complex inhibits RIPK3-dependent necrosis. Nature *471*, 363–367.

28. Fritsch, M., Günther, S.D., Schwarzer, R., Albert, M.C., Schorn, F., Werthenbach, J.P., Schiffmann, L.M., Stair, N., Stocks, H., Seeger, J.M., et al. (2019). Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature *575*, 683–687.

29. Newton, K., Wickliffe, K.E., Maltzman, A., Dugger, D.L., Reja, R., Zhang, Y., Roose-Girma, M., Modrusan, Z., Sagolla, M.S., Webster, J.D., and Dixit, V.M. (2019). Activity of caspase-8 determines plasticity between cell death pathways. Nature *575*, 679–682.

30. Rathkey, J.K., Zhao, J., Liu, Z., Chen, Y., Yang, J., Kondolf, H.C., Benson, B.L., Chirieleison, S.M., Huang, A.Y., Dubyak, G.R., et al. (2018). Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis. Sci. Immunol. *3*, eaat2738.

31. Yang, J., Liu, Z., Wang, C., Yang, R., Rathkey, J.K., Pinkard, O.W., Shi, W., Chen, Y., Dubyak, G.R., Abbott, D.W., and Xiao, T.S. (2018). Mechanism of gasdermin D recognition by inflammatory caspases and their inhibition by a gasdermin D-derived peptide inhibitor. Proc. Natl. Acad. Sci. USA *115*, 6792–6797.

32. Boya, P., and Kroemer, G. (2008). Lysosomal membrane permeabilization in cell death. Oncogene *27*, 6434–6451.

33. Kimura, T., Takabatake, Y., Takahashi, A., and Isaka, Y. (2013). Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res. *73*, 3–7.

34. Cheng, X.T., Xie, Y.X., Zhou, B., Huang, N., Farfel-Becker, T., and Sheng, Z.H. (2018). Revisiting LAMP1 as a marker for degradative autophagy-lysosomal organelles in the nervous system. Autophagy *14*, 1472–1474.

35. Pierzyńska-Mach, A., Janowski, P.A., and Dobrucki, J.W. (2014). Evaluation of acridine orange, LysoTracker Red, and quinacrine as fluorescent probes for long-term tracking of acidic vesicles. Cytometry A *85*, 729–737.

36. Yoshimori, T., Yamamoto, A., Moriyama, Y., Futai, M., and Tashiro, Y. (1991). Bafilomycin A1, a specific inhibitor of vacuolar-type H^+-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J. Biol. Chem. *266*, 17707–17712.

37. Kand, D., Saha, T., Lahiri, M., and Talukdar, P. (2015). Lysosome targeting fluorescence probe for imaging intracellular thiols. Org. Biomol. Chem. *13*, 8163–8168.

38. Paz, I., Sachse, M., Dupont, N., Mounier, J., Cederfur, C., Enninga, J., Leffler, H., Poirier, F., Prevost, M.C., Lafont, F., and Sansonetti, P. (2010). Galectin-3, a marker for vacuole lysis by invasive pathogens. Cell. Microbiol. *12*, 530–544.

39. Uchimoto, T., Nohara, H., Kamehara, R., Iwamura, M., Watanabe, N., and Kobayashi, Y. (1999). Mechanism of apoptosis induced by a lysosomotropic agent, L-leucyl-L-leucine methyl ester. Apoptosis *4*, 357–362.

40. Colacurcio, D.J., and Nixon, R.A. (2016). Disorders of lysosomal acidification—the emerging role of v-ATPase in aging and neurodegenerative disease. Ageing Res. Rev. *32*, 75–88.

41. McGuire, C., Stransky, L., Cotter, K., and Forgac, M. (2017). Regulation of V-ATPase activity. Front. Biosci. *22*, 609–622.

42. McGuire, C.M., and Forgac, M. (2018). Glucose starvation increases V-ATPase assembly and activity in mammalian cells through AMP kinase and phosphatidylinositide 3-kinase/Akt signaling. J. Biol. Chem. *293*, 9113–9123.

43. Stransky, L.A., and Forgac, M. (2015). Amino acid availability modulates vacuolar H^+-ATPase assembly. J. Biol. Chem. *290*, 27360–27369.

44. Lu, M., Ammar, D., Ives, H., Albrecht, F., and Gluck, S.L. (2007). Physical interaction between aldolase and vacuolar H^+-ATPase is essential for the assembly and activity of the proton pump. J. Biol. Chem. *282*, 24495–24503.

45. Smardon, A.M., Nasab, N.D., Tarsio, M., Diakov, T.T., and Kane, P.M. (2015). Molecular interactions and cellular itinerary of the yeast RAVE (regulator of the H^+-ATPase of vacuolar and endosomal membranes) complex. J. Biol. Chem. *290*, 27511–27523.

46. Stegh, A.H., Barnhart, B.C., Volkland, J., Algeciras-Schimnich, A., Ke, N., Reed, J.C., and Peter, M.E. (2002). Inactivation of caspase-8 on mitochondria of Bcl-x$_L$-expressing MCF7-Fas cells: role for the bifunctional apoptosis regulator protein. J. Biol. Chem. *277*, 4351–4360.

47. Hughes, M.A., Powley, I.R., Jukes-Jones, R., Horn, S., Feoktistova, M., Fairall, L., Schwabe, J.W., Leverkus, M., Cain, K., and MacFarlane, M. (2016). Co-operative and hierarchical binding of c-FLIP and caspase-8: a unified model defines how c-FLIP isoforms differentially control cell fate. Mol. Cell *61*, 834–849.

48. Pietkiewicz, S., Schmidt, J.H., and Lavrik, I.N. (2015). Quantification of apoptosis and necroptosis at the single cell level by a combination of imaging flow cytometry with classical annexin V/propidium iodide staining. J. Immunol. Methods *423*, 99–103.

49. Santos, L.C., Vogel, R., Chipuk, J.E., Birtwistle, M.R., Stolovitzky, G., and Meyer, P. (2019). Mitochondrial origins of fractional control in regulated cell death. Nat. Commun. *10*, 1313.